ImmunoGen, Inc. : Announces Activity Reported with SAR3419 Plus Rituxan In ... 4-traders (press release) ... technology, today announced the presentation of clinical findings with SAR3419 (coltuximab ravtansine) used in combination with Rituxan® (rituximab) to treat diffuse large B-cell lymphoma (DLBCL) that previously had been treated with standard ... |
